Introduction
Essential tremor (ET) is a common neurological disease with no known cure [1] . It shares a number of clinical features with Parkinson's disease (PD), another tremor disorder; furthermore, prospective epidemiological studies show that patients with ET are at increased risk of developing incident PD [2] . Patients with ET and PD have been reported to share a number of genetic risk factors, suggesting that there may be shared disease mechanisms [3] . For these reasons, association studies carried out in PD patients have often been extended to those with ET [4, 5] .
Patients with PD are well known to have an increased risk of developing melanoma; however, the exact mechanism is unknown [6, 7] . Considering the associations between ET and PD, we tested the hypothesis that ET would be associated with an increased odds of cancer, and particularly, an increased odds of melanoma and possibly other integumentary (i.e. skin and appendages) cancers. We also examined whether dystonia, another movement disorder, and one which commonly occurs in patients with PD [8, 9] , might be associated with these cancers. To perform these analyses, we capitalized on the enrollment of patients with ET, PD, dystonia as well as controls in research study of the epidemiology of movement disorders [10] .
Methods

Participants and Evaluation
ET cases, PD cases, dystonia cases, and controls were enrolled in a case-control study of the epidemiology of movement disorders at Columbia University Medical Center (CUMC; 2009-2014) [10] . Cases had all received a diagnosis of ET, PD, or dystonia from their treating neurologist, one of the movement disorder neurologists at the Neurological Institute, CUMC, and were confined to a geographical area within 2 h driving distance of CUMC [10] . One of the authors (E.D.L.) reviewed the office records of all selected patients, and confirmed the diagnoses of PD and dystonia using published diagnostic criteria for each [11, 12] . ET cases also underwent a videotaped tremor examination and diagnostic confirmation as described further below.
Controls were recruited during the same time period. These controls were identified using random digit telephone dialing within a defined set of telephone area codes that were represented by neurological cases within the New York Metropolitan area, and were selected from the same source population as the cases. There was one group of controls for all neurological disease cases (ET, PD, and dystonia). During recruitment, controls were frequencymatched to ET cases based on age. The CUMC Internal Review Board approved of all study procedures. Written informed consent was obtained upon enrollment. Analysis of data was also approved by the Internal Review Board at Yale Medical School.
It is important to note that the case groups and controls were all derived from the same geographic area in New York, a temperate climate zone. Hence, across the study groups, it is likely that there was a similar environmental exposure to sun.
During the in-person evaluation, the trained research worker administered clinical questionnaires (demographics, smoking history, and medications). This included a 10-15 min, 26-item, structured questionnaire that elicited data on the history of cancer. The questionnaire was an expansion of one used in an earlier study [13] , with additional questions abstracted from several validated cancer surveys [14] [15] [16] . The first 2 questions asked whether the participants (1) ever had cancer or (2) currently have cancer. The remaining questions were about the specific type of cancer according to the organ, years elapsed since initial diagnosis, recurrence, metastasis, and medical and surgical management. To validate the diagnosis of melanoma, one of the authors (S.Y.S.) contacted the participant's dermatologist and reviewed the medical record and pathology report with them over the telephone.
Medical comorbidity was assessed using the Cumulative Illness Rating Scale (CIRS), in which the severity of medical problems (0 (none)-3 (severe)) was rated in 14 body systems (e.g. cardiac, respiratory) and a CIRS score was assigned (range 0-42 (maximal co-morbidity)) to each participant [17] . Years since the last hospitalization, a measure of comorbidity, was also assessed. Tobacco exposure was assessed, and cigarette smoking was calculated in pack years; participants who never smoked were assigned '0' for pack years. We also recorded whether the participant had a diagnosis of diabetes mellitus, which has been associated with cancer [18] . Likewise, we collected data on the number of births, as a decreased number of live births in females is associated with certain types of cancers, such as endometrial cancers [19] . Also, it has been suggested that levodopa places PD patients at an increased risk of melanoma [20] . Based on a review of medical records, we recorded the most recent daily dosage of levodopa in PD.
All ET cases and controls had an in-person examination conducted by trained research staff during which time they underwent a standardized videotaped tremor examination, which included tests of postural and kinetic tremors and assessments for the presence of other involuntary movements. The aim was to use the videotape to carefully validate ET diagnoses (and lack thereof in controls) using rigorous research-grade diagnostic criteria [21] . Thus, each videotape was reviewed by a senior neurologist specializing in movement disorders (E.D.L.) who confirmed the ET diagnoses using Washington Heights-Inwood Genetic Study of ET diagnostic criteria (moderate or greater amplitude kinetic tremor (tremor rating ≥ 2) during 3 or more tests or a head tremor, in the absence of PD, dystonia or another cause) [21] .
Final Sample
To frequency-match (i.e. category match) by age and gender across all 4 groups, we excluded 149 (26.0%) of 574 enrollees. This matching was performed by selecting a group of individuals in each of the remaining diagnostic groups (PD, dystonia, controls) whose age and gender conformed to the distribution observed in the ET cases. This matching was performed within each diagnostic category blinded to all data other than age and gender. The final sample comprised 425 enrollees: 139 (100%) of 139 ET cases, 108 (80.6%) of 134 PD cases, 54 (44.6%) of 121 dystonia cases and 124 (68.9%) of 180 controls.
Definitions and Classifications
Cancers were categorized according to embryonic origin (ectodermal, mesodermal, endodermal, or mixed origin) as specified in the embryonic development, regenerative medicine and stem cell database [22] . The endoderm gives rise to the gastrointestinal tract and several other internal organs. The mesoderm gives rise to the dermis, muscles, blood, lymph, and other tissues. The ectoderm gives rise to the central nervous system (CNS). The integumentary system (i.e. skin and appendages such as hair) is composed of the epidermal layer (from the ectoderm) and the dermal and hypodermal layers (from the mesoderm). All integumentary cancers we recorded arise from the epidermal layer (ectoderm) except for squamous cell carcinoma, which originates from the dermis (mesoderm). Other organs are comprised of tissue that derives both from the ectoderm and mesoderm, and thus, we incorporated them in the mixed origin group. This group includes the breast, skin, and head and neck (oral cavity/pharynx) cancers.
The number of participants with cancer was defined as participants with a diagnosis of cancer. The number of cancer diagnoses for each cancer group type (i.e. ectodermal, mesodermal, etc.) was 
Statistical Analyses
Analyses were performed using the statistical software package SPSS (version 21.0; SPSS, Inc., Chicago, Ill., USA). We compared demographic and clinical characteristics across the 4 diagnostic groups (PD, ET, dystonia, controls; table 1 ). We also compared the mean carbidopa-levodopa dose in PD cases who did have vs. did not have melanoma (Student's t test). When variables were not normally distributed (i.e. Kolmogorov-Smirnov test statistic p value <0.05), non-parametric tests were used. Exact tests were used when appropriate. When a difference was detected across the 4 groups, we further compared each diagnostic group to controls (i.e. PD vs. controls, ET vs. controls, dystonia vs. controls). All tests were two-sided, and significance was accepted at the 5% level.
In the primary analysis ( table 2 a), we compared the prevalence of all cancer (ever) across diagnostic groups, the prevalence of melanoma (ever) across diagnostic groups, and the prevalence of cancers of integumentary origin (ever) across diagnostic groups. In the secondary analyses ( table 2 b), we compared the prevalence of all other types of cancer and cancers grouped according to embryonic origin across diagnostic groups. Given the large number of comparisons in the secondary analysis (n = 30; table 2 b), a significant p value for the secondary analysis was conservatively set at <0.0017 (i.e. 0.05/30); in this analysis, p values between 0.0017 and 0.05 were viewed as marginally significant.
To assess the relationship of any type of cancer, melanoma, and cancers of integumentary origin to the presence of ET, PD, or dystonia we used logistic regression analyses. We began with an unadjusted model. Then, in adjusted models, we first added variables (i.e. 'enter' function in SPSS) that were associated (p < 0.05) both with the movement disorder (ET, PD or dystonia separately) and with any type of cancer, melanoma, or cancers of integumentary origin (each explored separately). This was the 'conservative model', with more restrictive criteria for confounding. We then added variables that were associated with either the movement disorder or with any type of cancer, melanoma, or cancers of integumentary origin. This was the 'liberal model', with less restrictive criteria for confounding. These analyses generated ORs with 95% CIs. In some instances, the conservative model resembled the unadjusted model because no variables met stringent criteria for inclusion in the model.
Results
The 4 groups were similar with respect to age, gender, race, and education, as well as CIRS score, years since last hospitalization, diabetes mellitus, number of live births (females) and cigarette pack years ( table 1 ). The total number of prescription medications was significantly higher in PD, ET, and dystonia than controls ( table 1 ) .
The prevalence of all cancer and the number of cancer diagnoses were similar across the 4 groups ( table 2 a). The prevalence of melanoma differed across the 4 diagnostic groups (p = 0.003) and was higher in PD cases than controls (p < 0.001), and was marginally higher in ET cases (p = 0.08) and dystonia cases (p = 0.06) than controls ( table 2 a). The prevalence of integumentary cancer and/ or the number of such diagnoses was higher in PD cases than controls (p values <0.001) and marginally higher in In secondary analyses, cancers of ectodermal origin were significantly greater in PD than controls and there was a trend towards an increasing prevalence of basal cell cancers across groups ( table 2 b). Other cancers were similar across groups ( table 2 b).
We assessed in our control group whether demographic and clinical variables were associated with all cancer, melanoma, and integumentary cancers; older age and higher CIRS score were associated with all cancer ( table 3 ) .
In adjusted logistic regression analysis, the odds of any cancer was higher in PD cases than controls (OR 1.69 (conservative model) and OR 1.97 (liberal model); table 4 ). In adjusted models, the odds of melanoma was 7.09-9.84 times higher in PD cases than controls (p values 0.01-0.003), 3.73-4.10 times higher in ET cases than controls (p values 0.08-0.10), and 4.88-5.27 times higher in dystonia cases than controls (p values 0.06-0.07; table 4 ). The odds of integumentary cancer were 2.63-3.63 times higher in PD cases than controls in adjusted models (p values 0.001-0.0002) and 2.21-2.54 times higher in dystonia cases than controls (p values 0.03-0.07; table 4 ).
Fifty-one PD cases were taking carbidopa-levodopa. PD cases who had melanoma had a higher mean carbidopa-levodopa dose than PD cases who did not have melanoma (892.9 ± 591.2 (n = 7) vs. 523.3 ± 329.7 (n = 44), p = 0.03 (Student's t test)). In an analysis that removed PD cases who were taking levodopa, the odds of melanoma were higher in PD cases than controls (unadjusted OR 9.96, 95% CI 2.04-48.57, p = 0.004; liberal adjusted model OR 8.04, 95% CI 1.55-41.79, p = 0.01).
Discussion
We examined the relationship between cancer and 3 movement disorders, PD, ET and dystonia. PD was associated with an increased risk of cancer and particularly melanoma; the latter is a finding that has been reported previously and which has been the focus of considerable study [6] . We also detected a marginally significant association between ET and melanoma as well as between dystonia with melanoma, findings, which have not been reported previously. These data suggest that the links between certain neurological disorders and melanoma, which have long been known, may not be specific to PD and may extend to other movement disorders. This would suggest that the underlying mechanisms for the association may be broader than previously considered.
Different hypotheses have been proposed to explain the co-occurrence of melanoma and PD; however, the underlying mechanisms remain unclear [7] . Specific variants in the melanocortin 1 receptor gene are associated with PD, suggesting that these variants could modulate the risk of PD in the population [7] . DJ-1, a susceptibility gene for PD [23] , is expressed in uveal malignant melanoma cells [24] . Both the epidermal layer of the skin and the CNS are of ectodermal origin; therefore, it is interesting that melanoma is associated with certain disorders of the CNS. Moreover, the neurons that degenerate in PD are pigmented neurons, as are melanocytes. We are not aware of prior studies that have examined the association between ET and melanoma. The mechanisms for such an association are not clear, although ET and PD may share a number of biological mechanisms as well as genetic risk factors [3, 25] . Interestingly, in 2003, a study of a group of Caucasians of mixed European ancestry was conducted to test the hypothesis that lighter skin color (i.e. lower melanin) was associated with an increased risk of ET, but the study did not detect an association [26] . Confirmatory studies and additional research are needed.
We are similarly unaware of any prior study that examined the association between dystonia and melanoma. Animal studies suggest that alpha melanocyte-stimulating hormone (alpha-MSH) exerts dystonic action; microinjections of alpha-MSH into the locus coeruleus produce postures that are dystonic in nature [27] . Here, too, additional research is warranted.
The current data should also be interpreted within the broader context of the relationship between cancer and other neurodegenerative and neurological conditions aside from PD. Thus, studies have reported that individuals who are experiencing cognitive decline as well as those with Alzheimer's disease have decreased risk of cancer mortality [28, 29] .
Our data should be interpreted within the context of several limitations. First, most cancer diagnoses were by self-report, raising questions about their validity. Validation studies have supported the accuracy of self-reports as a measure of assessing prevalent chronic diseases [15, 30] . Furthermore, for our cancer of primary interest, melanoma, we confirmed the diagnoses with each participant's dermatologist based on the re-review of pathology reports. Our observation that PD is associated with melanoma, a finding that has been reported numerous times previously [6, 7] , further suggests that our patients' selfreports were valid. Another limitation is that this was a case-control study rather than a cohort study. Finally, the case groups and controls were all derived from the same geographic area in New York, a temperate climate zone. Hence, sun exposure is less than other climactic areas (e.g. near the equator) and greater than others (e.g. near the poles). This could limit the generalizability of our findings. Strengths of the study include the novelty of the question we pose (i.e. the association between cancers and other movement disorders aside from PD), the enrollment of more than 400 participants, the fact that cases had all received a diagnosis of ET, PD, or dystonia that Adjusted for number of prescription medications and years since last hospitalization. 4 The conservative model resembled the unadjusted model because there were no variables that met stringent criteria for inclusion in the model. Liberal models included variables that were associated either with the cancer in question or the diagnosis in question. Conservative models included variables that were associated both with the cancer in question and the diagnosis in question. was carefully assigned by a movement disorder neurologist, the inclusion of a disease group (PD) with wellknown increased odds of melanoma (i.e. enrollment of an internal control), the careful frequency-matching of our 4 study groups by age and gender, the fact that controls were carefully selected from the same source population as the cases, and the ability to assess and adjust for the effects of numerous potential confounding variables. In summary, we examined the relationship between 3 movement disorders, PD, ET and dystonia, and cancer. As reported often, PD was associated with increased odds of melanoma. A novel finding was the additional association, albeit marginal, between 2 other movement disorders, ET and dystonia, and melanoma. These data suggest that the links between neurological disorders and melanoma, long-known, may not be specific to PD and may extend to other movement disorders. Confirmatory studies are needed as well as cohort (i.e. incidence) studies, which attempt to establish the temporal relationship between these conditions. Studies that explore the mechanisms for these putative associations are also needed.
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